CELZ Creative Medical Technology Holdings Quick Ratio

Creative Medical Technology (CELZ) cellular platforms are patent-protected, creating sustainable demand for urological treatments and ensuring high margins. This chart illustrates that the asset's market value is 12.47. However, the company faces a liquidity shortage and is depleting reserves due to costly clinical trials, while management seeks to monetize tissue regeneration developments to combat diabetes and dysfunction.

The quick ratio assesses the ability of Creative Medical Technology (CELZ) to instantaneously settle short-term obligations without liquidating inventory. The calculation is based on the sum of cash and accounts receivable, excluding low-liquidity assets. Analyzing the acid-test ratio allows for the identification of working capital deficits. For Creative Medical Technology (CELZ), this is critically important, as geopolitical instability and logistical disruptions in Asia could sharply restrict access to resources.